ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 79

Functional Analysis of the Novel G58V Mutation in the TNFRSF1A Gene Identified in a Family with TNF Receptor-Associated Periodic Syndrome (TRAPS)

Shoko Kodama1, Hidenori Matsuzaki2, Tomoyuki Mukai1, Akiko Nagasu1, Masanori Iseki3, Nami Kurosaki1, Takafumi Mito1, Shunichi Fujita1, Takahiko Horiuchi4, Ryuta Nishikomori5 and Yoshitaka Morita1, 1Department of Rheumatology, Kawasaki Medical School, Kurashiki, Okayama, Japan, 2Department of Hygiene, Kawasaki Medical School, Kurashiki, Okayama, Japan, 3Department of Immunology and Molecular Genetics, Kawasaki Medical School, Kurashiki, Okayama, Japan, 4Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, 5Department of Pediatrics, Kyoto University Graduate School of Medicine, Kyoto, Japan

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Autoinflammation, Autoinflammatory Disease and Traps

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Session Title: Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis Poster I: The Variable World of Intercellular Signalling

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Mutations in the TNFRSF1A, which encodes tumor necrosis factor receptor 1 (TNFR1), are associated with the autosomal dominant disease TNF Receptor- Associated Periodic Syndrome (TRAPS). TRAPS is an autoinflammatory disease characterized by intermittent self-limited inflammatory episodes of fever. More than 100 heterozygous TNFRSF1A mutations associated with TRAPS or TRAPS-like clinical phenotype have been reported. T50M mutation and cysteine mutations are reported to cause intracellular accumulation of TNFR1 and exhibit a severe disease phenotype. Single nucleotide polymorphism in TNFR1, such as T61I and R92Q mutations, occurs in 1-5% of the general population and can be associated with a TRAPS-like phenotype. Therefore, there are multiple responsible mechanisms to induce inflammation in patients with TRAPS, and the molecular pathogensis is not yet fully understood. Recently we have identified a novel mutation, G58V (p.G87V) in TNFRSF1A, in two individuals in a family. They also had T61I mutation, and had suffered from recurrent episodes of intermittent fever and abdominal pain. In this study, we functionally characterized this novel G58V TNFRSF1A mutation.

Methods: The possible pathogenicity of the G58V mutation was analyzed using the four online prediction tools (SIFT, Polyphen2, PROVEAN and PANTHER). Wild-type (WT) or mutated TNFRSF1A (T50M, G58V, T61I, R92Q) constructs were generated by cloning the individual cDNAs into the pcDNA3.1 vector. The TNFR1 constructs were transfected into HEK-293 cells. Expression levels of the TNFR1 were examined by western blotting. To evaluate the NF-κB promoter activity, HEK-293 cells were transfected with the TNFR1 constructs along with NF-κB promoter-driven luciferase plasmid and the secreted alkaline phosphatase control vector pSEAP. NF-κB activation levels at 24 hours after the transfection were measured by the dual-luciferase reporter assay.

Results: The novel G58V mutation was predicted to be a highly damaging amino acid substitution that could cause a disease. The result is similar to those of pathogenic T50M and cysteine mutations. Expression levels of the WT and mutated TNFR1 proteins are comparable in the whole cell lysates of HEK-293 cells. NF-κB promoter activities in the T50M or the G58V TNFR1-expressing cells were significantly decreased compared to those in WT TNFR1-expressing cells (mean±SD; T50M 29.6±7.5% vs. WT 100±11.5%, p<0.001; G58V 40.1±0.9% vs. WT, p<0.001). The T61I mutation showed a small but significant reducation in NF-κB promoter activity (67.4±18.8%, p<0.05 vs. WT). In contrast, the R92Q mutation did not suppress NF-κB promoter activity (93.2±18.4%).

Conclusion: Consistent with a previous report (Blood 2006;108:1320-1327), the T50M mutation suppressed spontaneous NF-κB promoter activity, in spite of the clinical inflammatory features of TRAPS. The newly identified G58V mutation developed the similar phenotype to the pathogenic T50M mutation. These findings indicate that G58V could be a responsible mutation causing TRAPS.


Disclosure: S. Kodama, None; H. Matsuzaki, None; T. Mukai, Takeda Pharmaceutical Co., Ltd., 2,Pfizer Japan Inc., 2,Mitsubishi Tanabe Pharma Co., 2,Chugai Pharmaceutical Co., Ltd., 2,AbbVie GK, 2,TEIJIN Pharma Ltd., 2,Astellas Pharma Inc., 2,Japan Blood Products Organization, 2,Shionogi & Co., Ltd., 2,Actelion Pharmaceuticals Japan Ltd., 2,Eli Lilly Japan K.K., 2,DAIICHI SANKYO Co., Ltd., 2,UCB Japan Co. Ltd., 2; A. Nagasu, None; M. Iseki, None; N. Kurosaki, None; T. Mito, None; S. Fujita, None; T. Horiuchi, None; R. Nishikomori, None; Y. Morita, Takeda Pharmaceutical Co., Ltd., 2,Pfizer Japan Inc., 2,Mitsubishi Tanabe Pharma Co., 2,Chugai Pharmaceutical Co., Ltd., 2,AbbVie GK, 2,TEIJIN Pharma Ltd., 2,Astellas Pharma Inc., 2,Japan Blood Products Organization, 2,Shionogi & Co., Ltd., 2,Actelion Pharmaceuticals Japan Ltd., 2,Eli Lilly Japan K.K., 2,DAIICHI SANKYO Co., Ltd., 2.

To cite this abstract in AMA style:

Kodama S, Matsuzaki H, Mukai T, Nagasu A, Iseki M, Kurosaki N, Mito T, Fujita S, Horiuchi T, Nishikomori R, Morita Y. Functional Analysis of the Novel G58V Mutation in the TNFRSF1A Gene Identified in a Family with TNF Receptor-Associated Periodic Syndrome (TRAPS) [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/functional-analysis-of-the-novel-g58v-mutation-in-the-tnfrsf1a-gene-identified-in-a-family-with-tnf-receptor-associated-periodic-syndrome-traps/. Accessed January 27, 2023.
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/functional-analysis-of-the-novel-g58v-mutation-in-the-tnfrsf1a-gene-identified-in-a-family-with-tnf-receptor-associated-periodic-syndrome-traps/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences